AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Contingent Consideration Liability by Year
Contingent Consideration Liability — Current Portion [year-end] ($M) ($M)
AbbVie Contingent Consideration Liability: $3,455M in FY2025, up 33.4% from a year earlier.
Latest, FY2025
3,455
Period ended Dec 31, 2025
Change on a year earlier
+33.4%
2,589 in FY2024
History
5 years
Since FY2021
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 10 Financial Instruments & Fair Value.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Contingent Consideration Liability — Current Portion [year-end] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,455 | +33.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 2,589 | +32.6% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 1,952 | +32.9% | Form 10-K (filed 2025-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 1,469 | +17.6% | Form 10-K (filed 2024-02-20) ↗ |
| FY2021 | Dec 31, 2021 | 1,249 | – | Form 10-K (filed 2023-02-17) ↗ |
Cite this data
StockData. (2026). AbbVie Contingent Consideration Liability ($M), annual FY2021–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/cc-liab-cur
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.